Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
about
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsEmerging platforms using liquid biopsy to detect EGFR mutations in lung cancerBlood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-AnalysisLiquid biopsy genotyping in lung cancer: ready for clinical utility?Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients.The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis[Detection and evaluation of EGFR mutation status in serum of patients with advanced non-small cell lung cancer treated with EGFR-TKIs].Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis.Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-Analysis
P2860
Q26775376-4D33AC33-D492-4060-BB6E-763D7798240BQ28077340-4F29333F-85D0-499A-A0AA-4C61CE911031Q28077570-3DFCC435-F34D-4613-BB0E-4576392CCAB2Q28082499-E252A82E-77AF-40BC-8119-D9176BFA5A6FQ28087366-78C09403-1B5E-4571-9D0E-E69DE25EB4AFQ33567037-CD2205B3-3331-4EAD-9D1F-E8DA9D8F95CAQ33779727-D8871194-D7C1-460D-B961-D3EE0E2F57B8Q33829668-0626346A-26BA-437B-A651-578A4BD5C92CQ34092157-3964BBF1-25E4-4DA7-A770-6314E2B65952Q36095650-0072FE06-BFD7-4C9D-8DEF-C14B9FF3CF82Q36946809-E0EBC0F5-D6D1-437B-88AE-D95F451E129CQ37536958-CBA9F45B-5347-425F-827F-52F6CFCA44F8Q37743832-03A1D50A-FD10-47BC-9C00-CEA0BAE4A0A4Q45281573-123A4C25-3A3F-4347-B911-E3FED1257D3BQ47563363-701C508D-62A8-4A73-BC73-521FC8D1277FQ54369245-C0ED224D-1955-4CB0-BF07-72E988E253D5Q57147737-DC027456-37B4-48F5-8344-F77A3E625DD5
P2860
Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Can mutations of EGFR and KRAS ...... mall cell lung cancer (NSCLC)?
@en
Can mutations of EGFR and KRAS ...... ced non-small cell lung cancer
@nl
type
label
Can mutations of EGFR and KRAS ...... mall cell lung cancer (NSCLC)?
@en
Can mutations of EGFR and KRAS ...... ced non-small cell lung cancer
@nl
prefLabel
Can mutations of EGFR and KRAS ...... mall cell lung cancer (NSCLC)?
@en
Can mutations of EGFR and KRAS ...... ced non-small cell lung cancer
@nl
P2093
P2860
P1433
P1476
Can mutations of EGFR and KRAS ...... mall cell lung cancer (NSCLC)?
@en
P2093
Jae Sook Sung
Kyong Hwa Park
Sang Won Shin
Seung Tae Kim
Uk Hyun Jo
Yeul Hong Kim
P2860
P2888
P356
10.1007/S12032-012-0328-3
P577
2013-01-10T00:00:00Z
P6179
1024974047